PDK1 is a potential therapeutic target against angiosarcoma cells

Journal of Dermatological Science

Volumn 78, Issue 1, 2015, Pages 44-50

  Wada, Makoto ^a   Horinaka, Mano ^a   Yasuda, Shusuke ^a   Masuzawa, Mikio ^b   Sakai, Toshiyuki ^a   Katoh, Norito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

AKT independent; Cyclin D; PDK1

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CYCLIN D; DACTOLISIB; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P27; RETINOBLASTOMA PROTEIN; S6 KINASE; SMALL INTERFERING RNA; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PDPK1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANGIOSARCOMA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; IC50; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL LINE; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HEMANGIOSARCOMA; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RNA INTERFERENCE; SKIN NEOPLASMS; TUMOR CELL LINE;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE CELL CYCLE CHECKPOINTS; HEMANGIOSARCOMA; HUMANS; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84925969625     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.01.015     Document Type: Article

References (23)

1. Fayette J., Martin E., Piperno-Neumann S., Le Cesne A., Robert C., Bonvalot S., et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18:2030-2036.
2. Young R.J., Brown N.J., Reed M.W., Hughes D., Woll P.J. Angiosarcoma. Lancet Oncol 2010, 11:983-991.
3. Antonescu C.R., Yoshida A., Guo T., Chang N.E., Zhang L., Agaram N.P., et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69:7175-7179.
4. Przygodzki R.M., Finkelstein S.D., Keohavong P., Zhu D., Bakker A., Swalsky P.A., et al. Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. Lab Invest 1997, 76:153-159.
5. Weihrauch M., Bader M., Lehnert G., Koch B., Wittekind C., Wrbitzky R., et al. Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen 2002, 40:36-40.
6. Garcia J.M., Gonzalez R., Silva J.M., Dominguez G., Vegazo I.S., Gamallo C., et al. Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. Br J Cancer 2000, 82:1183-1185.
7. Italiano A., Chen C.L., Thomas R., Breen M., Bonnet F., Sevenet N., et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012, 118:5878-5887.
8. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N., et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997, 94:861-866.
9. LaMontagne K.R., Moses M.A., Wiederschain D., Mahajan S., Holden J., Ghazizadeh H., et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol 2000, 157:1937-1945.
10. Bundscherer A., Vogt T., Köhl G., Landthaler M., Hafner C. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. Anticancer Res 2010, 30:4017-4023.
11. Du W., Gerald D., Perruzzi C.A., Rodriguez-Waitkus P., Enayati L., Krishnan B., et al. Vascular tumors have increased S6-kinase activation and are inhibited by topical rapamycin. Lab Invest 2013, 93:1115-1127.
12. Masuzawa M., Fujimura T., Hamada Y., Fujita Y., Hara H., Nishiyama S., et al. Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J Cancer 1999, 81:305-308.
13. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996, 15:6541-6551.
14. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
15. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
16. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
17. Zhang S., Suvannasankha A., Crean C.D., White V.L., Johnson A., Chen C.S., et al. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 2007, 13:4750-4758.
18. Yacoub A., Park M.A., Hanna D., Hong Y., Mitchell C., Pandya A.P., et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006, 70:589-603.
19. Gao M., Yeh P.Y., Lu Y.S., Hsu C.H., Chen K.F., Lee W.C., et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res 2008, 68:9348-9357.
20. Perry B., Banyard J., McLaughlin E.R., Watnick R., Sohn A., Brindley D.N., et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007, 143:504-506.
21. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15:807-826.
22. Dennis P.B., Jaeschke A., Saitoh M., Fowler B., Kozma S.C., Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294:1102-1105.
23. Vasudevan K.M., Barbie D.A., Davies M.A., Rabinovsky R., McNear C.J., Kim J.J., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009, 16:21-32.